Citadel Advisors’s Sagimet Biosciences SGMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SGMT
Citadel Advisors's SGMT Position: Q3 2026 in Review
Citadel Advisors increased its Sagimet Biosciences (SGMT) stake by 27% in Q3 2026, buying an estimated $261K and bringing the position to 133,079 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #7773.
Citadel Advisors first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.09M in Q2 2024. 153 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.
- Citadel Advisors held 133,079 shares of Sagimet Biosciences worth $1.31M as of Q3 2026.
- Citadel Advisors bought 28,446 Sagimet Biosciences shares in Q3 2026, an estimated $261K.
- Sagimet Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #7773 holding.
- Citadel Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
- Citadel Advisors's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
- 153 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.